Outcome of stage III-B IgA-Kappa FLC MM with t(4:14) karyotype: A Nigerian jehovah witness nine-year experience


Author(s): Ogbonna Collins Nwabuko, Rapheal John

Multiple myeloma (MM) is the second commonest hematologic malignancy of public health importance after non-hodgkins lymphoma. It has been found to occur commonly among the Blacks. Unfortunately, there is poor case ascertainment of the disease in low-income countries (LICs) such as those in sub-Saharan Africa. The few newly diagnosed MM do not have access to a complete assessment tests making it difficult to stratify them and decide appropriate target therapy for their treatment. In this report, a 54-year old female who was diagnosed MM in Nigeria underwent risk stratification 9 years after. A complete assessment test showed a Stage III-A IgA-kappa FLC myeloma with 4;14 translocation and chromosome 13 deletion. She was on thalidomide-dexamethasone; melphalan-prednisolone and bortezomib-dexamethasone combination regimens at different cycles. She went into progression (cord compression fracture) 7 years after diagnosis She subsequently underwent laminectomy, but was lost to follow-up 3 years after.

Share this article

Editors List

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)

  • Skowronska-Gardas

    Department of Radiotherapy, Oncology Center-Institute (Warsaw, Poland)

  • Serban-Dan Costa

    Head of the Obstetrics and Gynecology Clinic of the University of Otto von Guericke (Magdeburg, Germany)